FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Rating On Shares Of Constellation Software Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our target price to CAD2,692 from CAD3,233, based on a P/E of 32x our 2027 EPS estimate, below its three-year average. We raise our 2026 EPS projection to USD57.58 from USD42.76 and increase our 2027 EPS view to USD61.41 from USD60.60. CSU reported Q1 2026 revenue of $3.18B, up 20% Y/Y, driven primarily by acquisitions, with organic growth of 6% (2% FX-adjusted). License revenue declined 9%, while Maintenance and recurring revenue, representing 77% of total revenue, grew 22% with strong 9% organic growth. Operating expenses increased 21%, slightly outpacing revenue growth and resulting in modest margin compression, while newly acquired businesses in Q1 2026 were also notably margin-dilutive, running at negative margins. Management expects margins to improve over time, though this warrants monitoring given its growth by acquisition strategy. Free cash flow available to shareholders rose 44% to $733M, reflecting a 380-bp expansion from Q1 2025.

Related Articles

Research

Research Alert: CFRA Keeps Sell Opinion On Shares Of Murphy Oil Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $2 to $31, reflecting a combination of our DCF and relative valuation models. On a relative basis, we apply a 4.0x multiple of enterprise value to projected 2027 EBITDA, slightly below peers, but we think a discounted multiple is reasonable, as we see a narrower surplus of operating cash flow to handle capex requirements than do most peers. This approach yields a value of $26 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 4% per year, terminal growth of 2%, discounted at a WACC of 6.1%, yields intrinsic value of $37 per share. We lift our 2026 EPS estimate by $2.56 to $3.89 but lower 2027's by $0.18 to $1.85. We see possible risk in 2027 from a commodity price downturn, which could crimp growth in capex spending, or growth in returns to shareholders. Our estimates for 2027 are a fair bit lower than consensus, which has less to do with company-specific factors, and more to do with our take on the macroeconomic view of crude oil prices.

$MUR
Research

Research Alert: Dox Posts In-line Quarter, Modest Backlog Growth; Maintains Fy 26 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DOX's Mar-Q results slightly exceeded expectations, with sales of $1.172B (+3.9% Y/Y) and non-GAAP EPS of $1.78 beating consensus views of $1.166B and $1.76, respectively. Constant currency sales growth again decelerated, coming in at 2.2% from the prior quarter's 3.5% rate, with managed services (65% of sales) slowing to 1.6% growth from 2.3% growth in Q1. Management narrowed its FY 26 guidance ranges, with sales growth now expected at 2.6%-4.6% (vs. prior 1.5%-5.5%) and EPS growth expected at 5%-7% (vs. prior 4%-8%). 12-month backlog grew 2.6% Y/Y to $4.28B, offering strong support for the company's modest sales growth outlook with minimal reliance on shorter-term discretionary work (which has been under pressure amid the uncertain macro environment). CFO Tamar Rapaport-Dagin will be leaving the company, with Tal Rozenfeld (Head of Finance) taking over effective June 2026, though we expect no material operating impact from the change.

$DOX
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Unitedhealth Group

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $440 from $385, 24x our 2026 EPS estimate (up $0.11 to $18.36; 2027 estimate up $0.64 to $20.76), a premium to UNH's 10-year historical forward average of 19.4x. Our target multiple is above most peers to reflect strong FCF generation, balance sheet strength, scale advantages, and a diversified business model across health insurance, pharmacy benefit management, health care technology and analytics, and outpatient facility networks. We are upgrading our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with UNH and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve.

$UNH